ch.oddb.org
 
Apotheken | Hôpital | Interactions | LiMA | Médecin | Médicaments | Services | T. de l'Autorisation
Information professionnelle sur Budenofalk® 4 mg suppositoires:Dr. Falk Pharma AG
Information professionnelle complèteDDDAfficher les changementsimprimé 
Composit.Forme gal.Indic./emploiPosolog./mode d'empl.Contre-Ind.PrécautionsInteract.Grossesse
Apt.conduiteEffets indésir.SurdosagePropriétésPharm.cinét.Donn.précl.RemarquesNum. Swissmedic
PrésentationsTitulaireMise à jour 
A07EA06 - BudesonideATC-DDD Version 2016. Source: WHO
A - Alimentary Tract and Metabolism
 
A07 - Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents
 
A07E - Intestinal Antiinflammatory Agents
 
A07EA - Corticosteroids Acting Locally

Enemas and rectal foams for treatment of e.g. ulcerative colitis are classified here. Oral corticosteroids solely indicated for the treatment of intestinal inflammatory diseases are also classified here.
Sublingual formulations of budesonide for the treatment of eosinophilic esophagitis and oral formulations of budesonide for the treatment of primary immunoglobulin A nephropathy are classified in this group.

The DDDs are given as 1 enema. The DDD for hydrocortisone rectal foam is given in amount of active substance.
The DDD for oral budesonide is based on the treatment of morbus Crohn. The DDD for the subligual formulations of budesonide are based on the treatment of eosinophilic esophagitis.

A07EA06 - Budesonide
Concentr.Adm.RouteNote
 S 
 O 
2024 ©ywesee GmbH
Einstellungen | Aide | FAQ | Identification | Contact | Home